CD8A and neoplasm: Combined with the patient’s clinical manifestations, we hypothesized that the immunosuppressed TME of CD8-predominant AITL leads to insufficient anti-tumor immunity, manifesting as an increase in tumor proliferation index, which in turn leads to tumor dissemination (40), causing aggravation of the patient’s clinical manifestations such as frequent effusion and edema.